Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey.
作者信息
Rodrigues Susana G
机构信息
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Clin Mol Hepatol. 2023 Jan;29(1):110-112. doi: 10.3350/cmh.2022.0414. Epub 2022 Dec 12.
Abstract
摘要
相似文献
1
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey.
Clin Mol Hepatol. 2023 Jan;29(1):110-112. doi: 10.3350/cmh.2022.0414. Epub 2022 Dec 12.
2
Correspondence on Editorial regarding "Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients".
Clin Mol Hepatol. 2023 Jan;29(1):188-190. doi: 10.3350/cmh.2022.0408. Epub 2022 Nov 22.
3
Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII.
Liver Int. 2023 Sep;43(9):1966-1974. doi: 10.1111/liv.15632. Epub 2023 Jun 8.
4
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5.
5
Evolving portal hypertension through Baveno VII recommendations.
Ann Hepatol. 2024 Jan-Feb;29(1):101180. doi: 10.1016/j.aohep.2023.101180. Epub 2023 Nov 19.
6
ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
Hepatol Int. 2022 Oct;16(5):1105-1115. doi: 10.1007/s12072-022-10345-4. Epub 2022 May 24.
7
Baveno VII - Renewing consensus in portal hypertension.
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
8
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.
J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3.
9
Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
J Hepatol. 2021 Sep;75(3):750-752. doi: 10.1016/j.jhep.2021.04.019. Epub 2021 Apr 20.
10
Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?".
J Hepatol. 2021 Sep;75(3):752-753. doi: 10.1016/j.jhep.2021.06.007. Epub 2021 Jun 17.
引用本文的文献
1
Evaluation of Noninvasive Tools for Predicting Esophageal Varices in Patients With Cirrhosis at Tygerberg Hospital, Cape Town.
Int J Hepatol. 2024 Sep 11;2024:9952610. doi: 10.1155/2024/9952610. eCollection 2024.
2
Risk Factors for Progressive Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C in India.
Cureus. 2024 Jul 15;16(7):e64550. doi: 10.7759/cureus.64550. eCollection 2024 Jul.
3
Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
World J Gastroenterol. 2024 Feb 21;30(7):685-704. doi: 10.3748/wjg.v30.i7.685.
4
Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases.
Cureus. 2024 Feb 14;16(2):e54206. doi: 10.7759/cureus.54206. eCollection 2024 Feb.
本文引用的文献
1
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5.
2
Non-invasive tests for clinically significant portal hypertension after HCV cure.
J Hepatol. 2022 Dec;77(6):1573-1585. doi: 10.1016/j.jhep.2022.08.025. Epub 2022 Sep 5.
3
A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Am J Gastroenterol. 2022 Nov 1;117(11):1825-1833. doi: 10.14309/ajg.0000000000001887. Epub 2022 Jul 21.
4
Baveno VII - Renewing consensus in portal hypertension.
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
5
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
6
The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?
Clin Mol Hepatol. 2021 Jan;27(1):91-93. doi: 10.3350/cmh.2020.0311. Epub 2020 Dec 3.
7
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.
J Hepatol. 2020 Nov;73(5):1023-1029. doi: 10.1016/j.jhep.2020.06.007. Epub 2020 Jul 1.
8
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients.
Hepatol Int. 2020 Sep;14(5):850-857. doi: 10.1007/s12072-020-10062-w. Epub 2020 Jun 15.
9
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
J Hepatol. 2019 Mar;70(3):412-422. doi: 10.1016/j.jhep.2018.10.018. Epub 2018 Oct 31.
10
Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
Hepatology. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. Epub 2016 Oct 27.
Zotero 插件